LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05
M-J. Ahn(Samsung Medical Center), Weili Gu(Fudan University), E. Pons-Tostivint(Centre Hospitalier Universitaire de Nantes), H. Hayashi(Kindai University), M. Pérol(Centre Léon Bérard), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Jacob Sands(Harvard University), Y. Goto(National Cancer Center Hospital East), E. Felip(Universitat Autònoma de Barcelona), Deise Uema(Daiichi Sankyo (United States)), Isamu Okamoto(Kyushu University Hospital), Elaine Shum(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Aaron Lisberg(APLA Health), K. Lakshmi Narayanan(Daiichi Sankyo (United States)), Shunichi Sugawara(Sendai Kousei Hospital), B.C. Cho(Seoul Medical Center), Min Hee Hong(Yonsei University)
Cited by 9
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k